Clinical trials: All Comers
Stable Angina, Unstable Angina
Clinical Performance of CRE8 Drug Eluting Stent in All Comer Population
The aim of this study is to evaluate safety and efficacy performances of CRE8 Drug Eluting Stent, in patients comparable to the everyday's clinical practice population, with a specific focus on diabetics, that will be part of a…
- Conditions
- Stable Angina, Unstable Angina, Acute Myocardial Infarction
- Trial name
- PARTICIPATE (NCT01556126)
- Testing
- Amphilimus Eluting Stent (CRE8)
- Where
- 23 sites in Austria, Belgium and 4 more
- Volunteers
- 1,191 people
- Sponsor
- CID - Carbostent & Implantable Devices
Aortic Valve Stenosis
TRANscatheter or SurgIcal Aortic Valve ReplacemenT in All-Comers With Severe Aortic Valve Stenosis
The purpose of this study is to determine that Transcatheter aortic valve replacement (TAVR) with SAPIEN 3 is superior to traditional surgical aortic valve replacement(SAVR) with bio-prosthesis regarding the rate of all-cause…
- Trial name
- TRANSIT (NCT02838199)
- Testing
- SAPIEN 3, SAVR
- Where
- South Korea
- Sponsor
- Seung-Jung Park
Peripheral Arterial Disease, Diabetes Mellitus
Comparing BlueDop Vascular Expert to Ankle-Brachial Index in the Identification of Peripheral Vascular Disease
To compare the screening capabilities of the BlueDop Vascular Expert (BVE) and ankle brachial index (ABI) in peripheral arterial disease for all-comer patients and those with diagnosed diabetes mellitus.
- Trial name
- NCT06436001
- Where
- United States
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Dakota Vascular
Hyperlipidemia, Cardio Vascular Disease
Rapid Escalation of LipiD Lowering Therapy to Reduce RecUrrent Cardiovascular Event
Hyperlipidaemia especially elevation of low-density lipoprotein cholesterol (LDL-C) is known to be the main contributor to the development of atherosclerotic cardiovascular disease (ASCVD).
- Trial name
- REDUCE-Lipid (NCT07311941)
- Where
- Hong Kong
- Volunteers
- 1,000 people
- Sponsor
- Chinese University of Hong Kong
Chronic Kidney Diseases, Coronary Artery Disease
Clinical Impact of Orsiro™ Stent in Patient With Chronic Kidney Disease
Orsiro™ or Orsiro_Mission™ stents have the biodegradable polymer and the thinnest stent strut (60㎛) in commercially available stents, which could minimize chronic inflammation and incomplete endothelialization.
- Trial name
- OKAY (NCT06475625)
- Testing
- Percutaneous coronary intervention, Orsiro™ or Orsiro_Mission™ stent
- Where
- South Korea
- Volunteers
- 3,113 people
- Sponsor
- The Catholic University of Korea
Peripheral Artery Disease
Acotec DCB Post Market Clinical Follow-up
All-comers, prospective, multi-center, single-arm, non-interventional post market clinical follow-up (PMCF) Cohort 1 - Claudicants: Rutherford Clinical Category (RCC) 2-3 Cohort 2 - Critical Limb Ischemia: Rutherford Clinical…
- Trial name
- FLOWER (NCT04393389)
- Testing
- AcoArt Orchid (0.035"), AcoArt Tulip (0.018") and AcoArt Litos (0.014") percutaneous transluminal angioplasty (PTA) paclitaxel drug coated balloon catheter manufactured by Acotec Scientific Co., Ltd.
- Where
- 7 sites in Germany
- Volunteers
- 3,000 people
- Sponsor
- Acotec Scientific Co., Ltd
Coronary Artery Disease, Angina Pectoris
Bioresorbable Polymer ORSIRO Versus Durable Polymer RESOLUTE ONYX Stents
The introduction of drug-eluting stents (DES) in the treatment of coronary artery disease has led to a significant reduction in morbidity.
- Conditions
- Coronary Artery Disease, Angina Pectoris, Unstable Angina Pectoris, Acute Coronary Syndrome
- Trial name
- BIONYX (NCT02508714)
- Testing
- Orsiro, Resolute Onyx
- Where
- 7 sites in Belgium, Israel and 1 more
- Volunteers
- 2,470 people
- Sponsor
- Thorax Centrum Twente
Coronary Artery Disease
BIOFLOW III Satellite-ELADIS Orsiro Stent System
This registry is a clinical evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES).
- Trial name
- NCT02029092
- Where
- 14 sites in Spain
- Volunteers
- 404 people
- Sponsor
- C.E.M. Biotronik, S.A.
Peripheral Arterial Occlusive Disease
"All Comers" Post Market Clinical Follow-up (PMCF) With Multi-LOC for flOw liMiting Outcomes (LOCOMOTIVE Extended)
The aim of the study is to assess the safety and efficacy of the Multi-LOC® peripheral stent system to treat de novo and restenotic lesions (no in-stent restenosis (ISR), no restenosis post drug coated balloon (DCB) after flow…
- Trial name
- NCT02900274
- Testing
- VascuFlex Multi-LOC®
- Where
- Germany
- Volunteers
- 353 people
- Sponsor
- B. Braun Melsungen AG
Acute Coronary Syndrome, Angina Pectoris
Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
Drug eluting stents (DES) are widely used for treatment of coronary artery lesions. The Xience Sierra stent has a refined design of the metal stent backbone and is used in patients with various clinical syndromes and in different…
- Conditions
- Acute Coronary Syndrome, Angina Pectoris, Angina, Unstable, Myocardial Infarction
- Trial name
- NCT04475380
- Testing
- Percutaneous coronary intervention
- Where
- 2 sites in Netherlands
- Volunteers
- 1,757 people
- Sponsor
- Foundation of Cardiovascular Research and Education Enschede
Coronary Artery Disease
Biofreedom Stent in All Comer Population
AIM OF THE STUDY: The aim of the present registry is to investigate the procedural as well as the long-term clinical results in terms of safety and efficacy of the polymer-free DES technology in all comers patients with an…
- Trial name
- NCT02858739
- Testing
- BIOFREEDOM STENT
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- University of Roma La Sapienza
All-comers
Physical Activity and Sedentary Behaviour Associated With Utilitarian E-bike Use
Physical inactivity and sedentary are recognized as important risks factors for several diseases and total mortality. One of the main perceived barriers to physical activity is the lack of time and motivation.
- Trial name
- VELONAPS (NCT03307473)
- Testing
- E6BIKE
- Where
- France
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- University Hospital, Clermont-Ferrand
Coronary Artery Disease
Everolimus- Versus Biolimus-Eluting Stents in All-Comers
This study sought to investigate safety and efficacy of biolimus-eluting stents (BES) with biodegradable polymer as compared with everolimus-eluting stents (EES) with durable polymer through 3 years of follow-up.
- Trial name
- EverBio (NCT01472705)
- Where
- Switzerland
- Volunteers
- 814 people
- Sponsor
- University of Freiburg
Aortic Valve Disease, Stroke
Swedish Study on STroke After TAVR
This study aims at studying the frequency of late stroke after transcatheter aortic valve replacement/implantation
- Trial name
- SWESTAT (NCT04086836)
- Testing
- TAVR
- Where
- Sweden
- Volunteers
- 4,600 people
- Sponsor
- Region Skane
Fracational Flow Reserve, Coronary Artery Disease
Preoperative Use of Fractional Flow Reserve in CABG Use and Effectiveness of FFR-based CABG in Real-life Practice
The use of fractional flow reserve (FFR) to guide coronary artery bypass graft (CABG) is controversial and not ubiquitously adopted across the units.
- Conditions
- Fracational Flow Reserve, Coronary Artery Disease, Coronary Artery Bypass Surgery
- Trial name
- NCT04379947
- Testing
- Fractional Flow reserve
- Sponsor
- University of Glasgow